SECTION 1
A 21-year-old man with no reported medical history presented to the emergency department complaining of bilateral blurry vision. His symptoms began abruptly 2 days prior to presentation, preceded by a thunderclap headache the week prior. Initial evaluation at an outside emergency department found a urine drug screen positive for cannabis, and his symptoms were misattributed to marijuana intoxication. The patient was a chronic, daily marijuana user. There was no family history of migraine, early-onset cerebrovascular or cardiovascular disease, or hypercoagulable state.
The neurologic examination was notable for uncorrected near visual acuity of 20/30 bilaterally. A right homonymous hemianopia was found on confrontational visual field testing. Pupillary reactivity and ocular motility was normal. No papilledema was evident. Facial and palatoglossal movements were normal. The patient was unable to read simple or complex sentences. Writing, fluency, repetition, comprehension, and object naming were intact. The remainder of the neurologic examination had normal results. There were no dermatologic or ocular abnormalities.
Questions for consideration:
1. What is the most likely neuroanatomic localization based on the examination findings? 2. What differential diagnoses should be considered at this point? SECTION 2 Right homonymous hemianopia localizes to the retrochiasmal afferent visual pathway (optic tract, optic radiation, or primary visual cortex) in the left hemisphere. The inability to read with preserved writing is termed "alexia without agraphia," which is a disconnection syndrome caused by involvement of the splenium of the corpus callosum. A lesion involving the left occipital cortex and adjacent splenium functionally disconnects the intact right hemispheric visual cortex from the left hemispheric language areas necessary for reading; this deficit is seen in left posterior cerebral artery (PCA) distribution infarcts. Additional clinical findings associated with left PCA infarction include hemiachromatopsia (impaired color vision), palinopsia, micropsia, macropsia (visuopsychic phenomena characterized by persistent image in the blind hemifield, and appearance of objects smaller or larger than expected, respectively), visual agnosia, Gerstmann syndrome (acalculia, agraphia, finger agnosia and right-left confusion), and aphasia (anomic or transcortical sensory). 1 Occasionally a single trunk off the PCA (artery of Percheron) supplies the bilateral thalamus and midbrain; in such cases, infarction is hallmarked by lethargy, memory disturbance, thalamic aphasia, sensorimotor impairment, and ophthalmoplegia.
Abrupt symptom onset should prompt consideration of a vascular etiology such as ischemic or hemorrhagic stroke. The heralding thunderclap headache raises the possibility of subarachnoid hemorrhage, cervicocephalic dissection, cerebral venous thrombosis, or reversible cerebral vasoconstrictive syndrome. Primary or secondary complications related to marijuana or other illicit substances are considerations. Infectious, neoplastic, and demyelinating processes warrant consideration but were believed to be less likely.
Brain MRI with and without contrast showed acute bihemispheric infarction in multiple arterial territories (figure). The left PCA distribution acute infarction involved the visual cortex and splenium of the corpus callosum resulting in the clinical syndrome of alexia without agraphia. Gradient-echo sequences were unremarkable. Four-vessel cerebral angiogram was normal. Laboratory testing was remarkable for a serum creatinine of 1.2 and EKG demonstrated a right bundle branch block. Evaluation with transthoracic and transesophageal echocardiogram and cardiac MRI were normal. Investigation for inherited or acquired prothrombotic states revealed heterozygosity for MTHFR mutation; homocysteine level was normal. Genetic susceptibility should be considered in young patients with stroke; a family history of stroke should prompt consideration of monogenic disorders that include stroke as a phenotype. Sickle cell disease is a significant hematologic contributor to arterial stroke due to prothrombotic state and progressive vasculopathy. The frequency of factor V Leiden mutation and antiphospholipid syndrome is 8% and 6%, respectively. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy is seen in 1%, similar to mitochondrial disorders (1%). The incidence of Fabry disease (FD) in young adults with unexplained stroke may be up to 1.2%.
Active malignancy leading to prothrombotic state is thought to contribute 1% of stroke. Drug-induced AIS has a similar frequency of 1%. Migraine is another risk factor, thought to be the cause in 1%-5%. Despite thorough testing, cryptogenic stroke accounts for approximately one-third of AIS in both young adults and children. [2] [3] [4] The association between marijuana use and stroke is unclear; fewer than 60 cases have been reported citing a temporal relationship. A causal relationship has not been established, largely due to lack of extensive neurovascular imaging and confounding factors including lifestyle and genetic predisposition. Postulated downstream effects of cannabis include impaired cerebral autoregulation, labile blood pressure, cardiac arrhythmias, vasculopathy, vasospasm, reversible cerebral vasoconstriction syndrome, and multifocal intracranial stenosis. The latter 2 are strong considerations in the mechanical pathogenesis of stroke associated with marijuana use. 5 Additional family history was elicited; the patient's sister developed progressive visual deterioration and painful acroparesthesias during adolescence. A maternal half-uncle developed early-onset renal failure requiring hemodialysis at age 32 years. The patient was able to recall a personal history of painful acroparesthesias beginning in adolescence.
Question for consideration:
1. What additional testing should be considered in light of the family history?
GO TO SECTION 4
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SECTION 4
Serum a-galactosidase A activity was found to be zero, strongly suggestive of FD. This patient had multisystem manifestations of FD, including abnormal cardiac conduction, arterial stroke, and early renal dysfunction. No angiokeratomas were present. Treatment with enzyme replacement was recommended prior to molecular testing results, given the absence of GLA enzyme activity and family history. In addition to genetic counseling, he was referred for hematologic, ophthalmologic, cardiology, nephrology, and dermatologic evaluations.
DISCUSSION FD is an X-liked genetic disorder associated with mutations of the GLA gene resulting in deficiency of a-galactosidase A activity, a lysosomal enzyme involved in lipid metabolism. Inefficient breakdown of lipids causes endothelial accumulation of globotriaosylceramide (Gb-3) in the kidneys, eyes, nervous system, and cardiovascular system. The incidence of FD is estimated at 1:40,000 to 1:117,000 male births, likely an underestimation due to nonspecific presenting symptoms and variability of presentation leading to misdiagnosis. FD occurs in all ethnic and racial groups. 6, 7 Clinical manifestations include acroparesthesias (75%, mean age at onset 10 years), angiokeratomas (greater than 70%, mean age at onset 14 years), impaired arterial circulation, cardiomyopathy, and arrhythmia (69% in males, 65% in females), leading to increased risk of myocardial infarction; corneal dystrophy (62% in males, 53% in females); tinnitus and hearing loss (57% in males, 47% in females); autonomic nervous system involvement including hypohydrosis, fever, and gastrointestinal discomfort (55% in males, 50% in females); renal dysfunction (50%, mean age at onset 35-40 years) and subsequent failure (17% in males, 1% in females) 7 ; and stroke (6.9% in males, 4.3% in females), predominantly in the posterior circulation due to basilar dolichoectasia. 8 The mechanism of stroke is not clearly understood; however, hypotheses include vasculopathy from accumulation of Gb-3, abnormality in cerebral blood flow, and prothrombotic state. 8 In our patient, chronic daily marijuana use may have conferred incremental risk to the development of arterial stroke given the underlying genetic predisposition from a-galactosidase A deficiency. Stroke may be a harbinger of disease and occurs before a diagnosis of FD is made in roughly 50% of cases. 8 Delays or diagnostic failure have negative implications on overall quality of life and survival time. The mean survival for men and women has been reported at 45.5 6 12.6 years and 55.4 6 14.9 years, respectively. Men frequently die of renal failure while cardiac disease is the most common cause of death in women. 7 Enzyme replacement therapy (ERT) is costly but improves life expectancy to the fifth or sixth decade.
ERT has yet to be proven to reduce future stroke risk.
9 ERT should be considered for patients with FD in addition to antiplatelet therapy, blood pressure reduction, glycemic control, and lipid lowering for those with stroke. Clinical trials using pharmacologic chaperone therapy to facilitate proper tertiary structure of a-galactosidase A show increased GLA activity and reduced Gb-3 accumulation in multiple organ systems. Chaperone therapy appears to be effective in mutations causing protein misfolding but is not effective for all mutations resulting in FD. 6 Clinicians should retain a high index of suspicion for FD when evaluating stroke in the young, given the multisystem involvement and the need for comprehensive multispecialty care for the best prognosis. All the respondents for this Mystery Case identified the patient's clinical syndrome as pure alexiaalso known as alexia without agraphia-and localized this syndrome to the dominant occipital lobe and splenium of the corpus callosum. A total of 75% of respondents recognized that the patient's clinical findings and family history are suggestive of FD; each of these respondents correctly identified a-galactosidase activity as the appropriate diagnostic test for this disorder.
STUDY FUNDING
The most complete answer came from Jeremy Cutsforth-Gregory from Mayo Clinic, who noted that the diagnostic test of choice for female patients is molecular genetic testing of the GLA gene. In heterozygous females, a-galactosidase activity is an unreliable indicator and may be within the normal range.
This case highlights a rare but treatable disorder with both neurologic and systemic manifestations, and underscores the importance of screening for systemic involvement to reach an accurate diagnosis.
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